We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Alnylam Announces Continued Progress on Development of its Intellectual Property Estate Covering RNAi Therapeutics

News   Jan 07, 2008

 
Alnylam Announces Continued Progress on Development of its Intellectual Property Estate Covering RNAi Therapeutics
 
 
 

RELATED ARTICLES

Epigenetic Signature May Help People Stay Ahead of IBD

News

In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.

READ MORE

Decoding the Structure of an RNA-Based CRISPR System

News

Over the past several years, CRISPR-Cas9 has moved beyond the lab bench and into the public zeitgeist. Now, scientists from the Salk Institute are reporting for the first time the detailed molecular structure of CRISPR-Cas13d, a promising enzyme for emerging RNA-editing technology.

READ MORE

Multiple Malware Threats for Visitors to Pirate Websites

News

Over 4 000 files containing malware or potentially unwanted programmes were retrieved from more than 1 000 websites suspected of sharing illegally protected content in an EU-wide research project carried out by the European Union Intellectual Property Office (EUIPO).

READ MORE

 

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE